Neurocrine biosciences to present study findings on evolving tardive dyskinesia education needs of physicians at the 2022 mds international congress

San diego , sept. 15, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (td) symptoms while maintaining control of the underlying psychiatric disorder.
NBIX Ratings Summary
NBIX Quant Ranking